Background {#Sec1}
==========

Cervical cancer is one of the common cancers in women worldwide. According to the World Health Organization, the incidence of cervical cancer ranks first in 28 countries and it is the leading cause of female deaths in 42 countries and it is estimated that 570,000 new cases and 311,000 deaths may occur worldwide in 2019 \[[@CR1]\]. In China, cervical cancer ranked 8th among the top 10 malignant tumors in 2015, accounting for 2.83% of all cancers. The incidence of cervical cancer in rural areas is higher than that in cities (6.34 and 2.68%, respectively) and the average age of onset of cervical cancer is 51 years, primarily in the 40--50 years age range. Cervical cancer rarely occurs before 20 years of age \[[@CR2]\].

Cervical cancer includes squamous cell carcinoma (SCC), adenocarcinoma (AC), adenosquamous carcinoma (ASC), neuroendocrine cancer, undifferentiated cancer, and other pathological types. SCC accounts for approximately 70% and AC accounts for approximately 25% cases \[[@CR3]\]. High-risk human papilloma virus (HPV) is a significant risk factor for cervical cancer. At present, more than 100 different subtypes of HPV have been found and 54 types able to infect the reproductive tract mucosa. High-risk subtypes include HPV16, 18, 31, 33, 35, 39, and 45. HPV16 and 18 subtypes are most closely related to cervical cancer \[[@CR4]\]. In recent years, HPV vaccines and screenings have reduced the incidence of cervical cancer in developed countries. However, the age-adjusted incidence rates of AC increased by 0.5 to 3% per annum in Europe \[[@CR5]\]. It is still controversial as to whether the pathological types of cervical cancer have an impact on the prognosis of patients. Some studies have shown that SCC and AC have the same overall survival (OS) \[[@CR6], [@CR7]\], while some data suggest that patients with AC of the cervix had poorer OS and disease-free survival (DFS) than patients with SCC \[[@CR3], [@CR8]--[@CR10]\].

In the current National Comprehensive Cancer Network (NCCN) guidelines, the standard treatment methods revealed no differences between SCC and AC of cervical cancer. However, the prognosis and clinical characteristics of SCC cervical cancer differs from that of AC cervical cancer. It has been reported that patients with AC tend to be younger and Caucasian, and they are more commonly diagnosed in the early stages of disease \[[@CR11]\].

Some studies have shown that, when compared with radiotherapy alone, concurrent radiotherapy combined with platinum-based chemotherapy can improve survival \[[@CR12]--[@CR17]\]. Since 1999, concurrent chemoradiotherapy has become the standard treatment approach for locally advanced cervical cancer regardless of the histological subtype of the disease. In recent years, some studies have suggested that total hysterectomy after neoadjuvant chemotherapy can improve survival outcomes of cervical cancer \[[@CR18], [@CR19]\]. This may be because neoadjuvant chemotherapy has the potential to eradicate micrometastases and could reduce systemic failures, in addition to facilitating local control by surgical resection. However, other studies have shown that the effect of neoadjuvant chemotherapy plus surgery does not show superiority compared to concurrent chemoradiotherapy \[[@CR20], [@CR21]\].

Therefore, we conducted this retrospectively study to analyze the data of patients with cervical cancer in Surveillance, Epidemiology and End Results (SEER) database to compare the survival outcomes of patients with SCC and those with AC among locally advanced cervical cancer patients as well as factors that are related to the prognosis of cervical cancer.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Information on patients diagnosed with cervical cancer between 2010 and 2015 was extracted from the SEER-18 Regs Custom database using SEER\*Stat software, version 8.3.6. We limited our sample to the period 2010--2015, as the information about some variables only are available from 2010. We included cervical cancer patients in our study using the following parameters: only one primary malignancy; International Federation of Gynecology and Obstetrics (FIGO,2009 version) stages IB2 to IVA; pathological biopsy confirmed SCC and AC; no distant metastases; aged 20 to 69 years; active follow-up with complete date; and complete clinicopathological information. Since the patient information in the SEER database is deidentified and publicly available, our study was exempt from Institutional Review Board approval. This study was conducted in concordance with the Helsinki Declaration.

Variables for each patient included: race, age, TNM stage, histology grade, T stage, N stage, pathological subtype, treatment strategy, survival time, and vital status. We restaged TNM stage according to the FIGO classification (2009 version). American Joint Committee on Cancer 7th edition (AJCC7) provided updated guidelines on the grading of cervical cancer. Patients were treated either with radiation alone, radiotherapy combined with chemotherapy, and/or surgery. Radiotherapy primarily included external radiation, brachytherapy, or external radiation combined with brachytherapy. The primary endpoint of this study was OS.

Statistics analyses {#Sec4}
-------------------

The baseline characteristics between cervical cancer patients in the AC and SCC groups were compared with chi-square (χ^2^) or continuity correction tests. A Cox proportional hazards model was used to perform univariate and multivariate analyses of the various factors affecting OS. As the baseline characteristics were different between two groups, propensity score matching (PSM) was performed with a ratio of 1:1. The matching covariates included race, age, TNM stage, histology grade, radiation sequence with surgery, radiotherapy and chemotherapy. Comparisons between the SCC and AC groups was evaluated by a two-side log-rank test before and after matching and OS was estimated using the Kaplan-Meier method. All analyses were performed using R statistical software (version 3.6.1, package includes survminer, rms, foreign, tableone, broom, matchlt, R Foundation) for statistical analysis. Hazard ratio (HR) and 95% confidence intervals (CIs) were compared between two groups. Two-sided *p* \< 0.05 was defined as statistically significant.

Results and conclusions {#Sec5}
=======================

Patient baseline characteristics {#Sec6}
--------------------------------

There were 4131 eligible patients who were diagnosed with stage IB2 to IVA cervical cancer between 2010 to 2015, including 3385 (81.9%) patients in the SCC group and 746 (18.1%) patients in the AC group. The detailed characteristics of patients in the SCC and AC groups before and after propensity score matching are shown in Table [1](#Tab1){ref-type="table"}. There were significantly more patients between the ages 40 and 49 in the AC group than in the SCC group (28.5% in the SCC group and 33.9% in the AC group, *P* = 0.02). The SCC and AC groups differed significantly when comparing the distribution of well differentiated (grade I) and undifferentiated (grade IV) cancer (4.2 and 1.5% in SCC group, 18.5 and 4.0% in AC group, *P* \< 0.001). There were more patients with FIGO stages IIB - IVA in the SCC group (82.8% in SCC group, 71.9% in AC group, P \< 0.001). The median survival time of patients in the SCC and AC groups was 33.6 (range, 0--83 months) and 35.8 months (range, 0--83 months), respectively (*P* = 0.013). Table 1Characteristics of cervical cancer patients with AC and SCC before and after matchingCharacteristicsBefore matchingAfter matchingAC (*n* = 746)SCC (*n* = 3385)*P* valueAC(n = 676)SCC(*n* = 676)P valueage (%)0.020.872  \< 40158 (21.2)840 (24.8)146 (21.6)143 (21.2) 40--49253 (33.9)965 (28.5)222 (32.8)236 (34.9) 50--59199 (26.7)947 (28.0)183 (27.1)179 (26.5) 60--69136 (18.2)633 (18.7)125 (18.5)118 (17.5)race (%)\< 0.0010.763 Black59 (7.9)568 (16.8)58 (8.6)62 (9.2) White596 (79.9)2476 (73.1)538 (79.6)527 (78.0) Other91 (12.2)341 (10.1)80 (11.8)87 (12.9)grade (%)\< 0.0010.928 I138 (18.5)142 (4.2)80 (11.8)77 (11.4) II313 (42.0)1610 (47.6)306 (45.3)297 (43.9) III265 (35.5)1583 (46.8)264 (39.1)276 (40.8) IV30 (4.0)50 (1.5)26 (3.8)26 (3.8)FIGO stage (%)\< 0.0010.923 Ib2142 (19.0)366 (10.8)118 (17.5)121 (17.9) IIa125 (3.4)81 (2.4)21 (3.1)14 (2.1) IIa242 (5.6)135 (4.0)35 (5.2)38 (5.6) IIb160 (21.4)732 (21.6)142 (21.0)143 (21.2) IIIa15 (2.0)75 (2.2)14 (2.1)11 (1.6) IIIb346 (46.4)1837 (54.3)331 (49.0)333 (49.3) IVa16 (2.1)159 (4.7)15 (2.2)16 (2.4)sequence (%)\< 0.0010.974 No surgery318 (42.6)2011 (59.4)308 (45.6)302 (44.7) RPTS55 (7.4)133 (3.9)45 (6.7)48 (7.1) RAS365 (48.9)1218 (36.0)315 (46.6)317 (46.9) RBAS8 (1.1)23 (0.7)8 (1.2)9 (1.3)Radiation (%)0.5270.25 Beam radiation328 (44.0)1487 (43.9)294 (43.5)323 (47.8) brachytherapy82 (11.0)328 (9.7)70 (10.4)70 (10.4) BRB336 (45.0)1570 (46.4)312 (46.2)283 (41.9)Chemotherapy (%)0.0170.865 Yes652(87.4)3060(90.4)596(88.2)599(88.6) No94 (12.6)325 (9.6)80 (11.8)77 (11.4)status (%)0.055 alive535 (71.7)2303 (68.0)480 (71.0)486 (71.9)0.763dead211(28.3)1082(32.0)196(29.0)190(28.1)time (mean (SD))35.8(21.4)33.6(21.7)0.01335.0(21.1)33.7 (21.5)0.269AC adenocarcinoma, SCC Squamous cell carcinoma, FIGO the International Federation of Gynecology and Obstetrics, RPTS Radiation prior to surgery, RAS Radiation after surgery, RBAS Radiation before and after surgery, BRB Combination of beam with brachytherapy. Grade I Well differentiated,gradeII Moderately differentiated,gradeIII Poorly differentiated,gradeIV Undifferentiated;SD Standard Deviation

Survivals of patients in SCC and AC groups {#Sec7}
------------------------------------------

To balance the baseline characteristics, 676 cervical patients with AC were matched 1:1 to patients with SCC. The baseline characteristics were similar between two groups after matching (Table [1](#Tab1){ref-type="table"}). The OS curves of patients with SCC and AC are shown in Fig. [1](#Fig1){ref-type="fig"}. The 5-year OS of patients in the SCC and AC groups were 16 and 18% (*P* = 0.67) before matching and were 16 and 17% after matching (*P* = 0.53). Fig. 1The overall survival (OS) of patients with squamous cell carcinoma (SCC) and adenocarcinoma (AC) (A) before propensity score matching (PSM) (B) after PSM

Univariate and multivariate analysis {#Sec8}
------------------------------------

In Table [2](#Tab2){ref-type="table"}, we present the results of the univariate analysis showing that histology was not a significant factor for OS. The univariate COX hazard ratio (HR) was 1.02 (95% confidence interval (CI) 0.93--1.12, *P* = 0.69). As shown in Table [2](#Tab2){ref-type="table"}, the primary univariate factors affecting OS were: FIGO stage IVA (HR = 0.74, 95% CI 0.57--0.98, *p* = 0.03), chemotherapy (HR 0.85, 95% CI 0.75--0.97, *p* = 0.01), race (HR = 1.20, 95% CI 1.03--1.39, *p* = 0.02) and external radiation combined with brachytherapy (HR 0.93, 95% CI 0.86--1.00, *p* = 0.06). Multivariate analysis found the same associated factors (Fig. [2](#Fig2){ref-type="fig"}). Table 2Univariate analysis of factors associated with OSVariablesUnivariate (OS)HR (95%CI)P valuehistology AC1.00 (reference) SCC1.02 (0.93--1.12)0.69age (%)  \< 401.00 (reference) 40--491.03 (0.93--1.13)0.61 50--590.97 (0.88--1.08)0.59 60--691.01 (0.90--1.14)0.81race (%) Black1.00 (reference) White1.06 (0.95--1.18)0.28 Other1.20 (1.03--1.39)0.02grade (%) I1.00 (reference) II1.07 (0.93--1.24)0.36 III1.00 (0.86--1.15)0.95 IV1.12 (0.82--1.53)0.47FIGO stage (%) Ib21.00 (reference) IIa11.02 (0.81--1.27)0.88 IIa21.17 (0.96--1.43)0.12 IIb0.98 (0.87--1.10)0.72 IIIa1.07 (0.80--1.42)0.64 IIIb1.00 (0.90--1.11)0.94 IVa0.74 (0.57--0.98)0.03sequence (%) No surgery1.00 (reference) RPTS0.88 (0.73--1.05)0.16 RAS0.93 (0.87--1.01)0.10 RBAS1.11 (0.72--1.73)0.63Radiation (%) Beam radiation1.00 (reference) brachytherapy0.98 (0.86--1.11)0.70 BRB0.93 (0.86--1.00)0.06Chemotherapy Yes1.00 (reference) No0.85 (0.75--0.97)0.01AC adenocarcinoma, SCC Squamous cell carcinoma, FIGO the International Federation of Gynecology and Obstetrics, RPTS Radiation prior to surgery, RAS Radiation after surgery, RBAS Radiation before and after surgery, BRB Combination of beam with brachytherapy, grade I Well differentiated,gradeII Moderately differentiated,gradeIII Poorly differentiated,gradeIV Undifferentiated;CI indicates confidence interval, HR hazard ratio

Subgroup analysis {#Sec9}
-----------------

For these analyses, we stratified patients by treatment and performed 1:1 matching on pathology. The detailed characteristics of subgroups after propensity score matching are shown in Table [3](#Tab3){ref-type="table"} and Table [4](#Tab4){ref-type="table"} .After matching, 15 cervical cancer patients with AC were matched with 15 patients with SCC (Fig. [3](#Fig3){ref-type="fig"}a) in the radiation only group. We showed that the OS of patients with SCC was significantly worse than that of patients with AC (*P* = 0.015). In the radiation combined with chemotherapy subgroup, we defined 282 matched pairs. The OS of patients receiving radiation combined with chemotherapy did not differ significantly by pathology (*P* = 0.62) (Fig. [3](#Fig3){ref-type="fig"}b). Figure [3](#Fig3){ref-type="fig"}c shows the OS comparing 49 matched subgroups treated with radiotherapy combined with surgery. Within this subgroup, the median survival time was shorter for AC patients, although these results were not statistically significant. Finally, we analyzed radiotherapy combined with chemotherapy plus surgery in 305 pairs and found that the OS of SCC and AC was very similar (*P* = 0.92) (Fig. [3](#Fig3){ref-type="fig"}d). Table 3characteristics of radiotherapy alone group and radiotherapy combined with chemotherapy group after matchingCharacteristicsRadiotherapy aloneCTRTAC (*n* = 15)SCC(n = 15)P valueAC(*n* = 282)SCC(n = 282)P valueage (%)0.8330.901  \< 402 (13.3)2 (13.3)41 (14.5)41 (14.5) 40--495 (33.3)6 (40.1)98 (34.8)100 (35.5) 50--594(26.7)2 (13.3)79 (28.0)84 (29.8) 60--694(26.7)5 (33.3)64 (22.7)57 (20.2)race (%)0.6480.969 Black2 (13.3)4(26.7)27 (9.6)27 (9.6) White13 (86.7)11 (73.3)36 (12.8)38 (13.5) Other0 (0.0)0 (0.0)219 (77.6)217 (76.9)grade (%)1.0000.991 I0 (0.0)0 (0.0)33 (11.7)34 (12.1) II4(26.7)5 (33.3)116 (41.1)114 (40.4) III11 (73.3)10 (66.7)124 (44.0)126 (44.7) IV0 (0.0)0 (0.0)9 (3.2)8 (2.8)FIGO stage (%)0.9700.012 Ib22 (13.3)1 (6.7)45 (16.0)25 (8.9) IIa11 (6.7)1 (6.7)5 (1.8)5 (1.8) IIa20 (0.0)1 (6.7)11 (3.9)7 (2.5) IIb2 (13.3)2 (13.3)77 (27.3)68 (24.1) IIIa1 (6.7)1 (6.7)10 (3.5)9 (3.2) IIIb7 (46.7)7 (46.7)127 (45.0)146 (51.7) IVa2 (13.3)2 (13.3)7 (2.5)22 (7.8)Radiation (%)0.7660.545 Beam radiation11 (73.3)11 (73.3)100 (35.5)91 (32.3) brachytherapy2 (13.3)3 (20.0)146 (51.7)159 (56.4) BRB2 (13.3)1 (6.7)36 (12.8)32 (11.3)status (%)1.0000.542 alive9 (60.0)9 (60.0)181 (64.2)173 (61.3) dead6(40.0)6(40.0)101(35.8)109(38.7)time(mean(SD))40.4 (32.5)26.1(18.6)0.15033.5 (21.6)31.8 (22.5)0.353AC adenocarcinoma, SCC Squamous cell carcinoma, FIGO the International Federation of Gynecology and Obstetrics, BRB Combination of beam with brachytherapy. CTRT radiotherapy combined with chemotherapy, grade I Well differentiated,gradeII Moderately differentiated,gradeIII Poorly differentiated,gradeIV Undifferentiated;SD Standard DeviationTable 4characteristics of radiotherapy plus surgery group and radiotherapy combined with chemotherapy and surgery group after matchingCharacteristicsradiotherapy plus surgeryCTRT plus surgeryAC(*n* = 49)SCC(n = 49)P valueAC(*n* = 305)SCC(n = 305)P valueage (%)0.7500.291  \< 409 (18.4)9 (18.4)84 (27.5)78 (25.6) 40--4917 (34.7)14 (28.6)101 (33.1)93 (30.5) 50--5916 (32.7)15 (30.6)74 (24.3)95 (31.1) 60--697 (14.3)11 (22.4)46 (15.1)39 (12.8)race (%)1.0000.56 Black3 (6.1)3 (6.1)17 (5.6)16 (5.2) White2 (4.1)2 (4.1)37 (12.1)29 (9.5) Other44 (89.8)44 (89.8)251 (82.3)260 (85.2)grade (%)0.5020.927 I1 (2.0)1 (2.0)33 (10.8)35 (11.5) II30 (61.2)25 (51.0)156 (51.1)153 (50.2) III17 (34.7)23 (46.9)109 (35.7)112 (36.7) IV1 (2.0)0 (0.0)7 (2.3)5 (1.6)FIGO stage (%)0.3780.066 Ib218 (36.7)17 (34.7)54 (17.7)34 (11.1) IIa13 (6.1)0 (0.0)11 (3.6)7 (2.3) IIa24 (8.2)3 (6.1)19 (6.2)9 (3.0) IIb5 (10.2)12 (24.5)57 (18.7)60 (19.7) IIIa1 (2.0)1 (2.0)2 (0.7)2 (0.7) IIIb16 (32.7)15 (30.6)159 (52.1)190 (62.3) IVa2 (4.1)1 (2.0)3 (1.0)3 (1.0)Radiation (%)0.6590.988 Beam radiation34 (69.4)34 (69.4)145 (47.5)144 (47.2) brachytherapy11 (22.4)13 (26.5)136 (44.6)136 (44.6) BRB4 (8.2)2 (4.1)24 (7.9)25 (8.2)status (%)1.000 alive40 (81.6)40 (81.6)234 (76.7)236 (77.4)0.923 dead9(18.4)9(18.4)71(23.3)69(22.6)time (mean (SD))37.9 (22.0)39.4(22.1)0.74937.3 (20.6)37.4(21.0)0.939AC adenocarcinoma, SCC Squamous cell carcinoma, FIGO the International Federation of Gynecology and Obstetrics, BRB Combination of beam with brachytherapy. CTRT radiotherapy combined with chemotherapy, grade I Well differentiated,gradeII Moderately differentiated,gradeIII Poorly differentiated,gradeIV Undifferentiated;SD Standard DeviationFig. 2Multivariate analysis of factors associated with OSFig. 3Treated with radiotherapy alone the overall survival (OS) of patients with squamous cell carcinoma (SCC) and adenocarcinoma (AC) (A); treated with radiotherapy and chemotherapy the OS of patients with SCC and AC(B), treated with radiotherapy and surgery the OS of patients with SCC and AC(C); treated with radiotherapy, surgery and chemotherapy the OS of patients with SCC and AC(D)

Discussion {#Sec10}
==========

Adenocarcinoma is a small pathological subtype in cervical cancer. In recent years, while the incidence of cervical cancer has generally declined \[[@CR22]\], the incidence of AC has increased \[[@CR5]\]. However, using the same treatment as for SCC may not be appropriate for AC patients \[[@CR23]\]. According to NCCN guidelines, the standard treatment for locally advanced cervical cancer is radiotherapy and concomitant chemotherapy using cisplatin, a protocol that was developed in SCC patients. As a result, there has been increasing interest in determining optimum treatments for AC. There are still considerable debates about the prognostic patterns between patients of AC and SCC as well as the proper treatment based on subgroup. ASC and AC cancers together represented 21.3, 22.9 and 24.1% of cases for the years 1988--1993, 1994--1999 and 2000--2005, respectively \[[@CR10]\]. A study based on the SEER database by Vijaya Galic, et al. showed that the incidence of AC and ASC was increasing 1--2% every 6 years \[[@CR9]\].

With this increasing pattern, researchers are increasingly interested in cervical AC. The literature shows that there is still a significant debate regarding the prognosis of patients with AC and SCC of the cervix. Some studies have shown that SCC of the cervix has a similar OS as that of AC \[[@CR6]\]. Other studies have shown that AC is less sensitive to radiotherapy than SCC of the cervix, especially in patients with poor prognostic factors \[[@CR8]\]. Therefore, in this study, we collected cervical cancer data from the SEER database to identify predictive factors associated with cervical cancer, and survival outcomes in patients with AC and SCC.

In 2011, a previous study by Katanyoo, et al. included a total of 423 patients with stages IIB--IVA and showed that the 5-year OS rates of AC and SCC were 59.9 and 61.7% (*p* = 0.191), respectively. When all prognostic factors were adjusted, clinical staging was the only factor that influenced OS \[[@CR6]\]. In 2014, Rose, et al. performed a retrospective analysis of 1671 patients with cervical cancer and suggested that when treated with radiotherapy alone, the OS of AC was worse than that of SCC. When the treatment was radiotherapy and concomitant platinum-based chemotherapy, the OS of patients is similar \[[@CR11]\]. In our study, we saw similar patterns. However, in 2018, Hu, et al. compared the treatment outcomes between SCC and AC of the cervix after definitive radiotherapy or concurrent chemoradiotherapy and showed that, when compared with SCC of the cervix, AC affected younger women, was more aggressive, and had more para-aortic metastatic lymph nodes. The 3-year disease-free survival, OS, local control rate, and distant control rate were worse for AC when compared to SCC \[[@CR3]\]. In the same year, a propensity score matching study by Yin, et al. enrolled 181 locally advanced cervical cancer patients who were treated with intensity modulated radiotherapy/volumetric modulated arc therapy and concurrent chemotherapy. The results showed that after a 1:1 ratio PSM, the 5-year OS, DFS, locoregional failure-free survival, and distant metastasis-free survival in the locally advanced cervical cancer of AC were 46.0, 43.3, 70.0, and 45.4%, respectively. These results were significantly lower than the corresponding rates of 90.0, 75.8, 96.6, and 78.8% in the matched locally advanced cervical cancer patients of SCC, respectively (*p* \< 0.05) \[[@CR24]\]. These studies showed a lower OS of AC in cervical cancer.

However, in the present study, we found that histology is not an independent factor of OS. Before PSM, the 3.5-year OS rates in the AC group were 44 and 18%, and the rates were 39 and 16% in the SCC group, respectively (*p* = 0.67). After PSM, the 3-year and 5-year OS of the AC group was 43 and 17%, compared to 40 and 16% in the SCC group (*P* = 0.53). There was no significant difference in OS between AC group and SCC group, regardless of matching status, leading to different conclusions from the previous studies. When comparing these studies, we did not exclude the impact of different treatments on the prognosis of the two pathological types. To make the results stronger, we divided the treatments into four groups and analyzed the difference between the AC and SCC groups.

In the subgroup analysis, when treated with radiotherapy alone, we found that the OS of patients with SCC was worse than that of patients with AC (*P* = 0.015), in contrast with other studies. The number of people in the analysis was small and the power to detect the difference between AC and SCC may have been too low. When we compared the treated with radiotherapy combined with chemotherapy or radiotherapy combined with chemotherapy plus surgery, the OS of patients with SCC and AC was similar (*P* = 0.62, *P* = 0.92). When treated with radiotherapy combined with surgery, the median survival time and the 3-year and 5-year OS of patients with AC was worse than patients with SCC. However there was no significant difference between two groups (*P* = 0.71). In univariable and multivariable analysis, the factors which had the strongest association with survival outcomes was FIGO stage, chemotherapy and external radiation combined with brachytherapy. The difference of study period, number of patients, criteria of enrolled patients, statistical methods and treatment modalities may help us understand the difference of our results when compared to the literature.

This study has some certain limitations. First, we used retrospective studies and we may have unintentional selectivity bias. Second, because the SEER database only recorded the sequence of radiotherapy and surgery, it did not record the sequence of surgery and chemotherapy, and we could not judge whether neoadjuvant therapy or adjuvant therapy is used in the treatment of cervical cancer patients. There was no recorded objective response time and disease-free survival time after treatment; therefore, we could not compare the difference between SCC and AC. In the future, we may need prospective clinical studies to confirm our conclusions.

Conclusions {#Sec11}
===========

Compared with SCC of the cervix, AC has similar OS when treated with radiotherapy combined with chemotherapy and/or surgery but with better OS when treated with radiation alone. Histology is not an independent factor of OS. The factors affecting the prognosis of cervical cancer are the FIGO stage, chemotherapy, race and external radiation combined with brachytherapy.
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